Subunit and mRNA vaccines against respiratory viruses, e.g., influenza or SARS-CoV2, are primarily focused on the induction of antibody responses to the envelope protein, e.g., hemagglutinin or spike and, for influenza, a neutralizing antibody titer is the primary accepted correlate of immunity [7,8]. This evidence concerns the gene ERVW-1 and influenza.